(OTC: KKUR) Publishes Further Proof of Its Cancer Detection Technology

  ChromoCure Inc., (PINKSHEETS: KKUR) announced
yesterday that they have published a pre-clinical system testing and
performance assessment on its Proprietary Chromosomal Scanner Technology in
the detection of cervical cancer through the detection of aneuploidy.

Recent studies suggest the aneuploidy theory is in the front and center of the carcinogenic process. Amongst others, Bert Vogelstein, MD, of John Hopkins confirms this theory in the Journal of National Cancer Institute, Vol. 97 No.2. The aneuploidy theory was further corroborated by Researchers at the Mayo Clinic. Their findings, which appear in the December 2009 issue of the journal "Cancer Cell" along with an independent commentary on the discovery, end a major controversy in the field of cancer research as to whether aneuploidy is a cause or a consequence of cancer and further proves the aneuploidy basis of cancer.

Given the new credibility of the chromosomal theory of cancer provided by the Mayo Clinic, the results of this performance study become immediately significant and relevant and further underscored both the correctness of the chromosomal basis of cancer as well as the performance of the company's technology.

Other active stocks Medical Care Technologies (OTCBB: MDCE), Medtronic Inc (NYSE: MDT) and ZOLL Medical Corp (NASDAQ: ZOLL)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact: Eric Jensen www.ionewswir.com 516.942.4910